Research
Bifidobacterium infantis
9 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Bifidobacterium infantis as a probiotic in preterm infants: a systematic review and meta-analysis.
Systematic review and meta-analysis of 67 RCTs evaluating probiotics in preterm infants, focusing on those containing B. infantis. Probiotics reduced the risk of NEC, LOS, and mortality, with greater reduction in NEC incidence in trials using B. infantis. Provides indirect evidence of B. infantis benefits for preterm infants.
Bifidobacteria-mediated immune system imprinting early in life.
RCT showing that supplementation with Bifidobacterium infantis EVC001 in breastfed infants silences intestinal Th2 and Th17 cytokines and induces interferon β, linking beneficial microbes to immunoregulation early in life.
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Meta-analysis assessing the efficacy of Bifidobacterium infantis 35624 in reducing IBS symptoms. Single probiotic B. infantis showed no significant impact, while composite probiotics containing B. infantis significantly reduced abdominal pain and bloating/distention.
Randomized, placebo-controlled trial reveals the impact of dose and timing ofprobiotic supplementation on breastfed infants' gut microbiome.
A 9-week randomized controlled trial with 40 exclusively breastfed infants aged 2-4 months tested the effects of Bifidobacterium infantis EVC001 supplementation on gut microbiome. The study found that probiotic supplementation increased fecal Bifidobacterium levels significantly compared to placebo, with colonization lasting at least 1 month post-supplementation.
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
RCT evaluating mesalamine and mesalamine+Bifidobacterium infantis 35624 in reducing gastrointestinal symptoms after acute diverticulitis. Mesalamine showed a consistent trend in reducing symptoms, with a higher rate of complete response compared to placebo at weeks 6 and 52. The addition of probiotic did not increase efficacy.
Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells.
The study investigated the effects of Bifidobacterium infantis administration on Foxp3 T regulatory cells in human peripheral blood. Results showed increased IL-10 secretion and enhanced Foxp3 expression, suggesting immunoregulatory responses that may have therapeutic utility in inflammatory diseases.
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
RCT of 77 IBS patients comparing Lactobacillus salivarius UCC4331, Bifidobacterium infantis 35624, and placebo over 8 weeks. B infantis 35624 significantly reduced IBS symptoms and normalized the IL-10/IL-12 cytokine ratio, suggesting an immune-modulating effect.
Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms.
Pilot RCT of probiotic Bifidobacterium infantis combined with bovine colostrum in children with ASD and GI co-morbidities. The combination treatment was well-tolerated, with mild gassiness as the most common side effect. Some participants experienced reduced GI symptoms and aberrant behaviors, potentially due to decreased IL-13 and TNF-α production.
Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease.
Exploratory RCT of 22 adults with untreated celiac disease testing Bifidobacterium infantis natren life start strain. The probiotic improved gastrointestinal symptoms but did not significantly affect intestinal permeability. Some immunologic changes were observed.